Cannabis Law Report

AUGUST 27, 2021

The Board will advise Delic and its subsidiaries, including Ketamine Infusion Centers, Delic Labs and others, as they develop safety protocols and best practices pertaining to legal psychedelic wellness treatments today and those legalized in the future. About Delic Corp, Inc.

Research and Development 98

Research and Development Treatment Media Medicine 98

Cannabis Law Report

NOVEMBER 23, 2021

London, UK – 23 November 2021 COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent and Trademark Office. PRESS RELEASE.

Clinical Trials 52

Clinical Trials Therapy Research and Development Media 52

United Patients Group

JUNE 8, 2023

It encourages patients to ask questions, provide accurate information, and participate in shared decision-making, leading to better treatment adherence and overall care quality. It replaces traditional paper-based forms and manual data entry, improving efficiency, accuracy, and patient experience. It also fosters active engagement.

Patients 52

Patients Data Collective Environment 52

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. On track to report top-line data by end of 2021. Net loss for the six months ended 30 June 2021 was $30.2 million, or $0.79 million) compared with $24.8 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

JULY 22, 2021

A master distribution agreement has been signed with My Green Planet, a leading global agricultural supply group, giving Sporeo access to approximately 7,000 retailers across North America, Australia, and Europe. Levitee Labs aims to catalyze access to compounds and alternative medicines that enhances the wellbeing of society.

eCommerce 105

eCommerce Therapy Media Access 105

Cannabis Law Report

NOVEMBER 9, 2021

(“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), a leader in new medicines and treatments for a modern world, today announced the official, completed acquisition of Ketamine Wellness Centers Arizona LLC (“KWC”), becoming the largest chain of wellness centers providing ketamine treatments in the U.S.

Treatment 52

Treatment Therapy Media Access 52

Puff Puff Post

MARCH 21, 2019

On March 8, the FDA granted the accelerated approval of Roche’s programmed cell death protein 1 (PD-1) inhibitor Tecentriq in combination with Abraxane (protein-bound paclitaxel) for the treatment of locally advanced or metastatic triple-negative breast cancer (TNBC). To gain access to our latest press releases: GlobalData Media Centre.

Data 92

Data Treatment Media Patients 92

Cannabis Law Report

SEPTEMBER 20, 2021

KWC is a limited liability corporation formed under the laws of Arizona , which operates 10 ketamine infusion treatment clinics, across Arizona , Colorado , Florida , Illinois , Minnesota , Nevada , Texas , and Washington. Transaction Highlights.

Treatment 52

Treatment Media Research and Development Patients 52

Veriheal

AUGUST 14, 2020

This data indicates a bit of an increase in cannabis use among expectant mothers over the course of about 15 years. . CNN and NBC both took a single study from Nature.com that also used this data as part of a study to explore neurodevelopmental outcomes in mothers who used cannabis during pregnancy. Be sure to tune in on Aug 25.

Data 52

Data Banking Media Policy 52

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. What if most of it is not based on the level of scientific certainty that cannabis marketing teams and media outlets would have us believe? The cannabis research problem.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Veriheal

JANUARY 4, 2021

In adults with chronic pain , what are the harms of Kratom or other plant-based substances for treatment of chronic pain? In adults with chronic pain, what are the benefits of Kratom or other plant-based substances for treatment of chronic pain? In adults with chronic pain, what are the harms of cannabinoids? A Statement from the AHRQ.

Chronic Pain 104

Chronic Pain Therapy Cannabinoids Treatment 104

Cannabis Law Report

NOVEMBER 22, 2019

MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”. . “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

JULY 6, 2021

Johnson’s primary area of research expertise is the psychopharmacology of medications for treating addictions, and he is well known in the field for his discovery that topiramate, a gamma-aminobutyric acid (GABA) facilitator and glutamate antagonist, an effective treatment for alcoholism. ” About Ehave, Inc. Ehave, Inc.

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

Cannabis Law Report

MARCH 17, 2022

COVID-related border restrictions did not cause immediate major interruption to Australia’s drug markets, but wastewater data strongly indicates that the cumulative effect of these restrictions led to some substantial market interruptions. The latest report presents data on Australia’s drug consumption for 12 substances.

Consumption 52

Consumption Programs Data Treatment 52

CannaMD

NOVEMBER 6, 2019

Perhaps the commercialization of marijuana and the favorable media coverage surrounding the health effects of marijuana are fostering such a perception. As more people gain access to medical marijuana, dependence on opioids for pain relief is likely to decline. Marijuana Preferred Over Pain Pills. percent, respectively. million to 11.4

Marijuana 87

Marijuana Patients Clinical Trials Data 87

Cannabis Law Report

SEPTEMBER 1, 2022

1 reason patients seek medical cannabis is to augment their pain management treatment. “The data is clear. We remain committed to advancing safe, legal access to this powerful medicine. For Media Inquiries Only: Callie Neatherlin. media@texasoriginal.com. “In the United States, the No. 512-439-9720.

Chronic Pain 52

Chronic Pain Programs Patients Conditions 52

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. At the same time, the outlook on cannabis research data is largely positive. Background. Refractory paediatric epilepsy.

Research and Development 52

Research and Development Medicine Access Media 52

Canna Law Blog

APRIL 13, 2019

The letters were sent “in response to their making unsubstantiated claims related to more than a dozen different products and spanning multiple product webpages, online stores and social media websites.” Specifically, the agency fears that.

CBD 90

CBD Safety Topical Food 90

Cannabis Law Report

JULY 24, 2019

But it is important that access to it is delivered in a way that fits in with other treatment options. We have the expertise to prescribe medicinal cannabis in a way that fits in with other more conventional treatments as and when we judge that to be in the best interest of the patients.

Epilepsy 40

Epilepsy Medicine Treatment Patients 40

Veriheal

DECEMBER 27, 2022

Researchers recruited 641 participants from Western Europe and America via Facebook groups, university mailing lists, and social media forums. The subjective nature of self-reported data can plague research. As a result, they possess more insight into climate change than individuals who don’t use psychedelics. Methamphetamine.

Research and Development 95

Research and Development Therapy Consumption DEA 95

Cannabis Law Report

AUGUST 31, 2022

1 reason patients seek medical cannabis is to augment their pain management treatment. The data is clear. We remain committed to advancing safe, legal access to this powerful medicine. For Media Inquiries Only: Callie Neatherlin. media@texasoriginal.com 512-439-9720. In the United States, the No.

Chronic Pain 52

Chronic Pain Programs Patients Conditions 52

Cannabis Law Report

JULY 29, 2021

We want to be an industry leader in preventing negative side effects during treatment and believe this can be of benefit to the entire industry.” Unlocking the genetic link will help point us towards treatment and a cure. Media Inquiries: Gabe Rodriguez. Forward-Looking Statement Disclaimer. Contact: Ehave Inc.

Research and Development 105

Research and Development Conditions Data Patients 105

Cannabis Law Report

JANUARY 13, 2020

commercial and government payors to ensure that appropriate patients have access to Epidiolex with as few restrictions as possible. Additional pipeline: Commence Phase 2b study of a cannabidiol formulation for the treatment of schizophrenia. Media Enquiries: Sam Brown Inc. media enquiries. Work with U.S. Christy Curran.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

MAY 6, 2022

Generally, a CBD product seller is expected (or required by law) to provide customers with access to a “certificate of analysis” or “COA” associated with specific products, which COA confirms the levels of CBD in products and upon which customers can rely. Delta-8 is known to be successful in many cancer treatments.”.

THC 52

THC CBD Media Food 52

Cannabis Law Report

SEPTEMBER 9, 2021

The collection of data for the final study was through focused interviews with a snowball sample of eight participants who have experienced trying to enter the cannabis industry in Western City, California. Data were analyzed based on the central question, and three themes emerged. Theme 3 involved access to capital.

Policy 105

Policy Research and Development Collective Banking 105

Freedom Leaf

JANUARY 4, 2018

After months of development, my partner and I built and successfully launched the beta for our cannabis data-analytics software, Jade Insights. It’s a software platform that helps cannabis businesses augment their process by providing insights for data-backed decision-making. ” JOHN KAGIA. ” OPHELIA CHONG.

Data 60

Data Policy Media Cannabis 60

Cannabis Law Report

OCTOBER 12, 2021

“Radicle Science has the potential to help dematerialize, demonetize and democratize clinical trials, and unlock a future of meaningful and abundant health products directly accessible by all.”. Media Contact: Eric Schudiske ( eric@s2spr.com ).

Clinical Trials 52

Clinical Trials Research and Development Sleep Cannabinoids 52

Cannabis Law Report

SEPTEMBER 24, 2019

Some parents, who have travelled to the Netherlands to buy cannabis medicines, feel the treatment will not help many children because it does not contain THC, which they argue has helped their children. These treatments can be prescribed only by specialist doctors in a limited number of circumstances where other medicines have failed.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

DECEMBER 15, 2021

In 2021, atai has achieved many major milestones, for example the promising phase 2a data for its schizophrenia drug RL-007 or the Phase 2b readout of Compass Pathways , of which atai owns 22.6% Constant change, misuse of social media, constant over-stimulation – all this is totally toxic for our brain and taking its toll on us all.

Research and Development 52

Research and Development Data History Patients 52

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Media coverage of the paper led to a new stigma and political pressure ended the Spain MDMA study. MAPS Founder Rick Doblin, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

The Cannigma

JANUARY 19, 2022

The resulting prejudice can often discourage folks from seeking out medical cannabis as an option, and can even affect state legislature, forcing patients to overcome unnecessary and prohibitive obstacles in order to receive the treatment they need. The Cannabis Enigma is a co-production of The Cannigma and Americans for Safe Access.

Patients 83

Patients Compliance Compliance Cannabis 83

Cannabis Law Report

DECEMBER 14, 2021

“Columbia Care’s mission has always been to provide patients with access to the highest quality, safest medicinal cannabis products available. We are proud to leverage our proprietary IP, formulation expertise, safety surveillance and patient reported data from the U.S. Media Lindsay Wilson. media@col-care.com.

Extraction 52

Extraction Patients Medicine Tincture 52

Cannabis Law Report

JANUARY 20, 2022

Eleusis pioneers the development of psychedelic drug candidates in the life sciences space, with the goal of transforming psychedelics into broadly accessible medicines. Eleusis designed ELE-Psilo, a proprietary psilocybin-based drug candidate that is formulated for IV infusion and in development for the treatment of depression.

Therapy 52

Therapy Research and Development Business Access 52

SpeedWeed

JULY 19, 2021

On June 23, Canada’s cannabis regulatory agency, Health Canada, released a private document requested under the Access to Information Act (AIA), that country’s version of the US government’s Freedom of Information Act. The data contained in that report has rocked the cannabis vaping world. The data was far worse than he imagined.

Vaping 52

Vaping Terpenes Data Research and Development 52

Cannabis Law Report

AUGUST 24, 2019

SOCIAL MEDIA: The measurable growth? On September 10, 2018, Katerina Eva Matsa and Elisha Shearer published a Pew Research Center viewpoint on use of social media News Use Across Social Media Platforms 2018. SOCIAL MEDIA: The setbacks? SOCIAL MEDIA + BANKING : The growth meets the setbacks ?

Banking 49

Banking Marijuana Media Patients 49

Greenspoon Marder Cannabis Law Group Blog

APRIL 2, 2019

For example, we’re seeking comments, data and information on a variety of topics including: what levels of cannabis and cannabis-derived compounds cause safety concerns; how the mode of delivery (e.g., For Alzheimer’s patients, CBD is one treatment option that is slowing the progression of that disease.”.

CBD 40

CBD Research and Development Safety Therapy 40

Cannabis Law Report

JUNE 4, 2021

there has never been a better time for new treatment options. Our proprietary ranking system takes into account: Social reach (social media, blogs, podcasts, publications, etc.). Through his social media outlets, podcast, blog, and interviews, Tim has educated hundreds of millions of people about psychedelics. Followers.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51